title: Effects of rifaximin on bacterial translocation in thioacetamide-induced liver injury in rats.
abstract: Intestinal bacterial overgrowth (IBO) and increased mucosal permeability are suggested to increase bacterial translocation (BT) in liver injury. Rifaximin (RIF) is a minimally absorbed oral antimicrobial agent that restores gut microflora imbalance. The aim of the present study was to investigate the effects of RIF on BT frequency in thioacetamide (TAA)-induced liver injury. Group 1 was the control. In group 2 (TAA), rats received TAA daily for 3 days. In group 3 (TAA + RIF), RIF was commenced on the same day as the first dose of TAA. In group 4 (RIF), rats received only RIF. Ileal aspirate Escherichia coli counts were significantly lower in the TAA + RIF group than in TAA group. There was no difference in BT frequency between the TAA and TAA + RIF groups. Our results suggest that factors such as intestinal barrier dysfunction and impaired host immune shield, apart from IBO, play an important role in BT in this model.
authors.affiliation: Department of Gastroenterology, Inonu University Medical Faculty, Malatya, Turkey. mharputluoglu@hotmail.com
authors.forename: Murat M M
authors.initials: MM
authors.lastname: Harputluoglu
authors.forename: Ulvi
authors.initials: U
authors.lastname: Demirel
authors.forename: Mehmet
authors.initials: M
authors.lastname: Gul
authors.forename: Ismail
authors.initials: I
authors.lastname: Temel
authors.forename: Sule
authors.initials: S
authors.lastname: Gursoy
authors.forename: Engin Burak
authors.initials: EB
authors.lastname: Selcuk
authors.forename: Murat
authors.initials: M
authors.lastname: Aladag
authors.forename: Yilmaz
authors.initials: Y
authors.lastname: Bilgic
authors.forename: Ercan
authors.initials: E
authors.lastname: Gunduz
authors.forename: Yuksel
authors.initials: Y
authors.lastname: Seckin
mesh_terms: D000818:Animals; D058491:Bacterial Load; D018988:Bacterial Translocation / Q000187:drug effects*; D056486:Chemical and Drug Induced Liver Injury / Q000188:drug therapy* / Q000382:microbiology* / Q000473:pathology; D004926:Escherichia coli / Q000254:growth & development* / Q000302:isolation & purification; D007082:Ileum / Q000187:drug effects / Q000382:microbiology*; D008099:Liver / Q000382:microbiology; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D012294:Rifamycins / Q000494:pharmacology* / Q000627:therapeutic use; D000078262:Rifaximin; D013853:Thioacetamide / Q000633:toxicity*
chemical_list: D012294:Rifamycins; D013853:Thioacetamide; D000078262:Rifaximin